ADIAL PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$7.8M | -$8.3M | -$6.9M | -$10.9M | -$19.3M |
| Operating expenses | $7.8M | $8.3M | $6.9M | $10.9M | $19.3M |
| Cash from operations | -$6.5M | -$6.9M | -$6.8M | -$11.2M | -$11.9M |
| Capital expenditure | — | — | — | — | $64,605 |
| Free cash flow | — | — | — | — | -$12.0M |
| Share repurchases | — | — | $1,661 | — | — |
| Impairments | — | — | — | — | $1.5M |
| Total assets | $6.7M | $5.0M | $4.7M | $5.7M | $7.5M |
| Total liabilities | $1.4M | $975,858 | $653,076 | $2.5M | $4.0M |
Shares outstanding 2.1M · Free float 2.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.